{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:23:54Z","timestamp":1788553434284,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019203","name":"ImmunoGen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019203","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41375-025-02571-0","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:47:42Z","timestamp":1742543262000},"page":"1243-1246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)"],"prefix":"10.1038","volume":"39","author":[{"given":"Frances M.","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Laszlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-5575","authenticated-orcid":false,"given":"Margaret C.","family":"Lunn-Halbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-566X","authenticated-orcid":false,"given":"Allie R.","family":"Kehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-523X","authenticated-orcid":false,"given":"Patrick A.","family":"Zweidler-McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Nyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-9220","authenticated-orcid":false,"given":"Sheryl Y. T.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-3558","authenticated-orcid":false,"given":"Camryn M.","family":"Pettenger-Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sribalaji","family":"Lakshmikanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"2571_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2571_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75:46\u201367.","journal-title":"CA Cancer J Clin"},{"key":"2571_CR3","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","volume":"24","author":"E Pelosi","year":"2023","unstructured":"Pelosi E, Castelli G, Testa U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int J Mol Sci. 2023;24:2718.","journal-title":"Int J Mol Sci"},{"key":"2571_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2:848\u201358.","journal-title":"Blood Adv"},{"key":"2571_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2022-158030","volume":"140","author":"N Daver","year":"2022","unstructured":"Daver N, Montesinos P, Aribi A, Marconi G, Altman JK, Wang ES, et al. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2022;140:62.","journal-title":"Blood"},{"key":"2571_CR6","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2023-173413","volume":"142","author":"N Daver","year":"2023","unstructured":"Daver N, Montesinos P, Altman JK, Wang ES, Martinelli G, Roboz GJ, et al. Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia. Blood. 2023;142:2906.","journal-title":"Blood"},{"key":"2571_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25:388\u201399.","journal-title":"Lancet Oncol"},{"key":"2571_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000535628","volume":"147","author":"J DiGennaro","year":"2024","unstructured":"DiGennaro J, Sallman DA. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: current guidelines, therapies, and future considerations. Acta Haematol. 2024;147:175\u201385.","journal-title":"Acta Haematol"},{"key":"2571_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","volume":"123","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Gudgeon CJ, Harrington KH, Dell\u2019Aringa J, Newhall KJ, Means GD, et al. Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123:554\u201361.","journal-title":"Blood"},{"key":"2571_CR10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/cancers16050877","volume":"16","author":"MC Lunn-Halbert","year":"2024","unstructured":"Lunn-Halbert MC, Laszlo GS, Erraiss S, Orr MT, Jessup HK, Thomas HJ, et al. Preclinical characterization of the anti-leukemia activity of the CD33\/CD16a\/NKG2D immune-modulating TriNKET\u00ae CC-96191. Cancers. 2024;16:877.","journal-title":"Cancers"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02571-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:46:45Z","timestamp":1746532005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02571-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PAZ-M reports previous employment with ImmunoGen (now AbbVie). SL reports employment with AbbVie. RBW received laboratory research grants and\/or clinical trial support from Celgene\/Bristol Myers Squibb, ImmunoGen\/AbbVie, Janssen, Jazz, Kite, Kura, Pfizer, and Vor Biopharma, and has been a consultant to Wugen. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All laboratory research described in this article was conducted under a broad research protocol approved by the Fred Hutchinson Cancer Center Institutional Review Board (Fred Hutch IRB; protocol #9045). Biospecimens from adults with AML were obtained from an institutional repository under protocol #1690 approved by the Fred Hutch IRB; all patients provided written informed consent for sample collection and use for research. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}